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Abstract 
Background and aims 
Over time, the majority of patients with Crohn's disease (CD) will develop irreversible 
gastrointestinal (GIT) damage, notably strictures or fistulas, impacting negatively on quality 
of life and resulting in hospitilisation and surgery. Early and aggressive drug therapy with 
immunomodulators (IMMs) and biologics may alter the likelihood of these complications and 
improve long-term outcomes. However, this approach is extremely expensive and carries its 
own battery of side-effects such as infections and malignancy. In addition there are a sizable 
number of patients with CD who will have a benign disease course and never require potent 
medical therapies or surgical intervention. As a result, there has recently been a surge of 
interest in early identification of those people who are at risk of developing complicated 
disease. The aim of our study was thus to indentify predictive factors for poor outcome CD in 
a South African setting, in order to select those who would most benefit from early and 
aggressive medical therapies.  
 
Methods 
A study protocol for a retrospective cohort study of CD patients attending the Inflammatory 
Bowel Disease clinic at Groote Schuur Hospital (GSH) was drawn up and submitted to the 
University of Cape Town Ethics Committee. Following approval, an extensive literature 
review was carried out to identify factors that have been shown to predict poor outcome CD 
in other populations. Information pertaining to patient demographics, clinical and 
biochemical factors at first diagnosis and subsequent disease course and complications was 
extracted. Eligible patients were retrospectively monitored from the time of CD diagnosis 
until the 31
st
 of December 2011, or alternatively, until the development of predefined 
endpoints of disabling CD (DCD) or severe CD (SCD). In all cases the patient records were 
recalled and manually searched to retrieve pertinent information. This study population 
consisted of CD patients diagnosed between 1980 and 2006 with minimum disease duration 
of five years and complete data at baseline. Patients were excluded if there was incomplete 
follow up. Two different definitions of poor outcome CD were evaluated according to 
predefined criteria: (1) DCD within five years of diagnoses and (2) SCD over the entire 
disease course. Clinical, demographic, laboratory and biological factors associated with these 
outcomes were evaluated by univariate and multivariate analysis. For the first part of the 
study, risk factors for the development of DCD within five years of diagnosis were analysed 
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using logistic regression analysis. For the second part of the study risk factors at diagnosis 
associated with time to the development of SCD over the entire disease course were 
evaluated using Cox proportional hazards analysis. 
 
Results 
Complete data was obtained for 120 patients. Seventy two percent developed DCD within 5 
years of diagnosis; on multivariate analysis only perianal disease (OR 11.0, 95% CI 1.1-94.7, 
p=0.03) and ileal involvement at diagnosis (OR 5.4, 95% CI 2.1-13.9, p<0.001) were 
predictive. The presence of these two risk factors yielded a sensitivity of 90% and a PPV of 
81%. Overall, the rate of SCD was 38% (45/120). On Cox proportional hazards analysis 
penetrating disease behaviour (HR2.9, 95% CI 1.2-7.0, p=0.02), stricturing disease behaviour 
(HR 4.6, 95% CI 1.5-14.6, p=0.01), perianal disease (HR 3.4, 95% CI 1.6-7.2, p=0.01) and 
the presence of tissue granulomas (HR 2.5, 95% CI 13-4.6, p=0.01) at diagnosis were 
independently associated with time to the development of SCD. When analysis was restricted 
to patients with non-stricturing, non-penetrating CD at diagnosis perianal disease and tissue 
granulomas were again strongly associated with the time to development of SCD. These two 
risk factors were highly specific for SCD and yielded a positive predictive value (PPV) of 
89%. 
 
Conclusion 
At the time of first diagnosis of CD factors predictive of future severe disease were 
stricturing or penetrating phenotype, perianal disease and tissue granulomas. Patients with 
these risk factors would most benefit from early and aggressive medical therapies. 
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Part A. Study protocol 
This protocol was submitted to the Research Ethics Committee of the University of Cape 
Town. Approval was given on the 20
th
 August 2012. 
 
Protocol approval number: HREC REF: 425/2012. A copy of the approval letter is filed as 
Appendix 1 
1.0 Background and literature review 
 
Crohn's disease (CD) is a form of Inflammatory Bowel Disease (IBD) which may affect any 
part of the gastrointestinal tract (GIT) in a discontinuous fashion from mouth to anus, most 
commonly involving the terminal ileum (TI). It is characterised histologically by non-
necrotising granulomatous inflammation that is trans-mural in nature. CD is a life-long 
disorder which may manifest at any time from childhood to late adulthood, most commonly 
in the late teens and early twenties; with over 80% diagnosed before the age of 40 years. CD 
is a progressive disorder, the behaviour of which evolves in most patients over time to be 
complicated by the development of strictures, fistulas or abscesses (Cosnes et al. 2011). At 
diagnosis, more than 80% have purely inflammatory luminal disease, but at 10 years more 
than half will have progressed to complicated stricturing and fistulising phenotypes, often 
requiring hospitalisation (Cosnes et al. 2002; Louis et al. 2001). Ultimately, 80% will 
undergo surgery (Mekhjian et al. 1979). The prevalence of perianal complications also 
increases with disease duration, from 12% one year after diagnosis to 26% after twenty years 
(Hellers et al. 1980). This disease progression varies enormously between patients; the course 
can be indolent with prolonged periods of remission, or alternatively it can follow an 
aggressive, incapacitating path with rapid development of these complications.  
 
Over the past decade, there have been major advances in medications available to treat CD, 
notably biological therapies such as infliximab and adalimumab which target tumour necrosis 
factor alpha (TNF). In addition, there has been an evolution in treatment paradigms with 
conventional immunomodulators (IMMs) such as azathioprine, 6-mercaptopurine and 
methotrexate now being introduced far earlier in the disease course, in an attempt to change 
the natural history of CD and improve long-term outcomes (Cosnes et al. 2005). It is 
becoming increasingly apparent that the early and aggressive use of potent therapies such as 
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biologics and/or IMMs, even at first diagnosis, may potentially modify the progressive and 
destructive course of CD and result in better outcomes (Colombel et al. 2010; D’Haens et al. 
2008). Consequently, contemporary thinking has shifted in favour of early treatment with the 
most efficacious therapies available, before the development of irreversible damage and 
complications, in an attempt to prevent debilitating and disabling CD down the line. 
 
However, such aggressive strategies are not without substantial risk of toxicity and adverse 
events such as infections and malignancy (Lichtenstein et al. 2005; Toruner et al. 2008). A 
major concern when using anti-TNFs in the South African context is the potential risk of 
disseminated tuberculosis (TB). In addition, population-based studies have shown that a 
sizable number of CD patients will have a benign course, which means they will never 
require surgery and never suffer a flare-up severe enough to warrant corticosteroids 
(Munkholm et al. 1995). To subject these individuals to drugs with potentially serious side 
effects is inappropriate. In addition, these medications (biologics) are extremely expensive 
and access is limited in resource-challenged environments such as ours. As such, there is a 
pressing need to identify factors early in the course of CD (ideally at diagnosis) which will 
help to predict future outcomes and identify those subgroups of patients who will develop 
poor outcome CD and who will receive greatest benefit from early and aggressive therapy. 
Equally important is the need to identify people who will likely have a benign course of CD, 
so as to avoid subjecting them to potentially toxic and unnecessary therapies.  
2.0 Study rationale 
 
In light of the potential risk of progression to complicated CD over time, and the lack of local 
evidence regarding which patients are at risk, the aim of this study is to evaluate the 
association between clinical and laboratory indices at the time of first diagnosis and 
subsequent adverse disease outcomes among CD patients receiving care at a tertiary hospital 
in Cape Town. 
 
Our specific objectives are three-fold: 
1. To validate clinical factors at first diagnosis of CD, previously shown in French and 
Belgian populations to be predictive of a disabling disease course within five years. 
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2. To explore the association between additional clinical, biochemical and histological 
factors at diagnosis and the development of disabling CD (DCD) within five years of 
diagnosis. 
3. To explore the association between additional clinical, biochemical and histological 
factors at diagnosis and time to the development of severe CD (SCD) over the entire 
disease course. 
 
No other study has been done in South Africa to analyse factors at diagnosis predicting the 
subsequent development of poor outcome CD. This is an extremely important research 
question given our limited local access to expensive disease modifying CD medications. 
Currently anti-TNF therapy is restricted to a total of 14 CD patients in our clinic, less than 
3% of our entire CD cohort. Being able to better predict which patients will develop 
aggressive complicated CD will allow more appropriate use of such scarce resources. In 
addition we could spare those who will likely have a benign course exposure to medications 
that place them at risk of active TB, a major concern given that the majority of our clinic 
patients reside in areas where TB is endemic. 
 
In addition, it is important that this research question is addressed using a local population, as 
our clinic patients differ from those treated in the West. The most crucial contextual factor is 
that common genetic CD-susceptibility mutations seen in the developed world are not a 
feature of CD in our clinic population (Zaahl et al. 2005). As such, one questions the 
generalisability of findings from European cohorts as it is unclear if these would be 
applicable to South African patients with CD. 
 
3.0  Study Methods 
3.1 Study design 
A retrospective cohort study will be conducted using an existing database and registry of CD 
patients attending the IBD clinic at Groote Schuur Hospital (GSH) in Cape Town. 
Information pertaining to subject demographics, clinical, biochemical and histological factors 
at first diagnosis and subsequent disease course and complications will be identified. The 
patients will be retrospectively followed-up from the time of CD diagnosis until the 31
st
 of 
December 2011 or alternatively until the development of predefined endpoints of DCD or 
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SCD or date of death. In all cases the patient case records will be recalled and manually 
searched to retrieve this information.  
This retrospective study design has been chosen as it can potentially answer the research 
question as efficiently as a prospective study, which is not feasible in our setting. Being able 
to answer this question would be invaluable in guiding therapy of newly diagnosed CD. 
3.2  Study setting/population 
The IBD clinic of the Gastro-Intestinal (GIT) unit at Groote Schuur Hospital (GSH), South 
Africa is to our knowledge the largest dedicated IBD clinic on the African continent. It is a 
tertiary referral centre which provides care to almost all IBD state patients within the Western 
Cape; those on medical aid schemes are invariably seen in the private sector but are often 
referred to GSH in the event of complications. IBD is not managed by primary or secondary 
care facilities in Cape Town. The clinic only sees patients over the age of 12 years; those 
younger are seen at the Red Cross Children’s Hospital and referred to GSH at the age of 13. 
 
Inclusion criteria 
1. A confirmed diagnosis of CD  
2. A minimum of five years of follow-up from time of diagnosis 
 
Exclusion criteria 
1. Revision of the initial diagnosis to Intestinal TB, Ulcerative colitis or IBD-U 
(unclassified) 
2. Incomplete data at baseline  
3. A patient that has not been seen at the clinic within the preceding 12 months 
4. The presence of complex perianal disease at diagnosis 
5. Surgical resection within one month of diagnosis  
 
The following data will be collected and recorded on an Excel spreadsheet: 
 
At diagnosis 
Demographics: age, gender, race, date of CD diagnosis, duration of follow-up 
Clinical factors at diagnosis: disease location (as per the Montreal classification: Appendix 
3), extent of small bowel involvement (in centimetres), number of colonic segments involved 
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(ascending colon, transverse colon, descending colon, sigmoid colon and rectum, to a 
maximum of five), corticosteroid use, family history of IBD, history of appendicectomy, 
smoking status, disease behaviour (as per the Montreal classification: Appendix 3) 
Biochemical factors at diagnosis: haemoglobin, white cell count, platelet count, C reactive 
protein (CRP) and albumin 
Histology at diagnosis: the presence or absence of epithelioid granulomas 
 
During follow up 
Within five years of diagnosis: further corticosteroid use after diagnosis, further 
hospitalisation after diagnosis, surgery, creation of a definitive stoma, progression from B1 to 
B2 or B3 phenotypes (as per the Montreal classification: Appendix 3), IMM use, biologic use 
Over the entire disease course: surgical resections, the development of complex perianal 
fistulas, and creation of a definitive stoma 
 
Definitions  
Stricturing disease will be defined as per the Montreal classification as ‘the presence of 
constant luminal narrowing demonstrated on radiologic, endoscopic or surgical-pathologic 
methods with pre-stenotic dilatation and/or obstructive signs and symptoms, without the 
presence of penetrating disease’. 
 
Penetrating disease will be defined as per the Montreal classification as ‘the occurrence of 
intra-abdominal inflammatory masses, abscesses and/or fistula’. If stricturing and penetrating 
complications are found simultaneously, the phenotype will be considered as penetrating. 
 
The definition of current smoking will be patients who smoke seven or more cigarettes per 
week. 
  
Complex perianal disease is defined as per the American Gastroenterology Association 
recommendation as ‘fistulas that are high intersphincteric, high transsphincteric, 
extrasphincteric or suprasphincteric , have multiple external openings, are associated with a 
perianal abscess, fistulise to adjacent organs, are associated with the presence of an anorectal 
stricture or associated with the presence of active rectal disease’ (Sandborn et al. 2003) 
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3.3  Study endpoints 
The two endpoints that will be analysed are: 
 
DCD (as defined by Beaugerie et al. 2006): ‘when within five years at least one of the 
following criteria is present  
1. More than two steroid courses required and/or dependence on steroids 
2. Further hospitalisation after diagnosis for flare-up or complications of the disease 
3. Presence of disabling chronic symptoms (cumulative time of more than 12 months of 
disabling symptoms: diarrhoea with nocturnal and/ or urgent stools, intense abdominal 
pain, extra-intestinal manifestations) 
4. The need for IMMs 
5. Intestinal resection or surgery for perianal disease’ 
 
SCD (as defined by Loly et al. 2008): ‘any one of the following criteria over the entire 
disease course 
1. The development of complex perianal disease 
2. Any colonic resection 
3. Two or more small-bowel resections (or a single small-bowel resection measuring more 
than 50 centimetres in length) 
4. The construction of a definitive stoma’ 
4.0 Statistical analysis 
 
For the first part of the study, the association between all baseline risk factors and the 
development of DCD within five years of diagnosis will be assessed by univariate analysis. 
The distribution of all continuous variables will be evaluated and expressed as medians and 
interquartile ranges (IQR) or means ± standard deviations (SD) as appropriate. Statistical 
analysis will employ Chi2, Fishers exact, Student t test, Wilcoxon rank sum test or Kruskal-
Wallis testing as appropriate. Those variables with P values below 0.10 will be further tested 
in a series of logistic multivariate regression models. The analysis will be performed using 
STATA version 11 (StataCorp. 2009. Stata Statistical Software: Release 11. College Station, 
TX: StataCorp LP). In the second part of the study, the association with the time to the 
development of SCD will be assessed by univariate and multivariate analyses using the Cox 
proportional hazards model. Kaplan-Meier curves will be generated. First, univariate models 
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will be constructed to produce the crude (unadjusted) hazard ratios for SCD according to the 
risk factors evaluated. Different models based on different combinations of risk factors will 
be fitted and compared to select the most clinically relevant and economical model. P values 
less than 0.05 will be considered to be statistically significant. The best model will be 
validated using the residuals; Cox-Snell residuals to assess overall model fit and Schoenfeld 
residuals to ensure that the proportional hazards assumption is upheld. 
5.0 Ethical considerations 
The database that will be used to identify patients has been in existence for over a decade and 
has given rise to several studies for which Ethical approval has been granted in the past. To 
ensure subject confidentiality, only the principal investigator will have access to the identity 
of these patients. Any patient information which may allow identification will not be 
divulged to any persons and will not appear in the dissertation or any subsequent 
publications. 
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Part B: Literature review 
1.0 Introduction 
 
Idiopathic inflammatory bowel disease (IBD) comprises a heterogeneous group of conditions 
affecting the gastrointestinal tract (GIT). Crohn's disease (CD) and ulcerative colitis (UC) are 
the two commonest forms of IBD. UC is limited to the colon and is characterised by 
continuous superficial inflammation. In contrast, CD may affect any part of the GIT in a 
discontinuous fashion from mouth to anus, most commonly involving the terminal ileum (TI). 
CD is characterised histologically by non-necrotising granulomatous inflammation that is 
transmural in nature. CD is a life-long disorder which may manifest at any time from early 
childhood to late adulthood. Typically, however, CD is diagnosed in the late teens and early 
twenties, with over 80% before the age of 40 years.  
2.0 The natural history of Crohn’s disease 
 
CD is a heterogeneous disorder which manifests with diverse clinical phenotypes. These 
phenotypes are currently defined by the Montreal classification system into sub-categories 
depending on the age at diagnosis, disease location and disease behaviour (Silverberg et al. 
2005). This classification is listed in Appendix 3. CD location within the gastrointestinal tract 
remains relatively constant over time; approximately 20% have isolated CD of the colon, 
30% have isolated small bowel involvement while 50% will have CD involving both the 
ileum and colon. Upper GIT CD is much less common and is seen in less than 10% of cases. 
Disease behaviour is defined by the presence or absence of intestinal complications such as 
strictures or fistulas and is categorised as inflammatory non-stricturing, non-penetrating CD 
(B1), stricturing CD (B2) or penetrating CD (B3). Stricturing disease is also known as 
stenosing or fibrostenotic disease. Penetrating disease is also known as perforating or 
fistulising CD and can be complicated by abscess formation.  
 
CD is a progressive disorder and the natural history varies enormously between patients. The 
course can be indolent with prolonged periods of remission, or alternatively it can follow an 
aggressive, incapacitating path. In contrast to disease location, CD behaviour evolves in most 
patients over time. At diagnosis more than 80% have purely inflammatory, non-stricturing 
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and non-penetrating disease, but at 10 years more than half will have progressed to 
complicated stricturing and fistulising phenotypes, often requiring hospitalisation (Cosnes et 
al. 2002; Louis et al. 2001). Ultimately 80% will undergo surgery (Mekhjian et al. 1979). 
The prevalence of perianal complications also increases with disease duration, from 12% one 
year after diagnosis to 26% after 20 years (Hellers et al. 1980). As such it is clear that CD 
more often than not, is a chronic, progressive disorder which results in cumulative, 
irreversible, structural damage to the GIT and the all the complications thereof.  
 
The current burden of IBD in the Western Cape is unclear; the last attempt to measure the 
magnitude of CD in the greater Cape Town area was in the 1980s (Wright et al. 1986). At 
that time the incidences of CD in the coloured, white and black population groups were 
calculated to be 1.8, 2.6 and 0.3/100 000 per year respectively. Very likely this incidence will 
have increased over the past 25 years, a trend that has been noted in both developed and 
developing countries worldwide (Cosnes et al. 2011). This is supported by the large numbers 
of CD patients treated at our referral tertiary IBD clinic, which cares for approximately 600 
individuals with the condition. As such, CD represents an important chronic condition which 
has far reaching local health and socioeconomic implications.  
3.0 The treatment of Crohn’s disease 
 
Over the past decade, there have been major advances in medications available to treat CD. 
This is most notable in the adv nt of biological therapies, in particular those agents targeting 
tumour necrosis factor alpha (anti-TNFs) such as infliximab and adalimumab. In addition, 
there has been an evolution in treatment paradigms as data has emerged on how best to use 
available therapies in order to improve long term outcomes (Colombel et al. 2010). While 
immunomodulators (IMMs) such as the purine analogues (azathioprine and 6-
mercaptopurine) and methotrexate have long been used in CD, the timing of their 
introduction has changed and they are being introduced far earlier in the disease course, in an 
attempt to change the natural history of CD (Cosnes et al. 2005). It is becoming increasingly 
apparent that the early and aggressive use of potent therapies such as biologics and/or IMMs, 
even at first diagnosis, may potentially modify the progressive and destructive course of CD 
and result in better outcomes (Colombel et al. 2010; D’Haens et al. 2008). Current thinking 
has thus shifted towards early treatment with the most efficacious therapies available, before 
the development of irreversible damage and complications, in an attempt to prevent 
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debilitating and disabling CD down the line. However, such aggressive strategies are not 
without substantial risk of toxicity and adverse effects such as infections and malignancy 
(Lichtenstein et al. 2005; Siegel et al. 2009; Toruner et al. 2008). A major concern when 
using anti-TNFs in our setting is the potential risk of disseminated tuberculosis (TB). In 
addition, population based studies have shown that a sizable number of CD patients will have 
a benign course, never require surgery and never suffer a flare-up severe enough to warrant 
corticosteroids (Munkholm et al. 1995). To subject these individuals to drugs with potentially 
serious side effects is inappropriate. In addition, these medications (biologics) are extremely 
expensive and access is limited in resource challenged environments. As such, there is a 
pressing need to identify factors early in the course of CD (ideally at diagnosis) which will 
help to predict future outcomes and identify those subgroups of patients who will develop 
poor outcome CD and who will receive greatest benefit from early and aggressive therapy. It 
is equally important to identify people who will likely have a benign course of CD, so as to 
avoid subjecting them to potentially toxic therapies.  
4.0 Predicting poor outcome Crohn’s disease 
 
Predicting poor outcome CD has been the subject of much interest in Europe and the USA, 
and several prognostic factors have been identified at the time of diagnosis and used to build 
predictive models and guide therapeutic decision making. Unfortunately interpreting this data 
is hindered by the lack of a standardised definition of poor outcome CD, which is subjective 
and differs between studies (Louis et al. 2009; Yarur et al. 2011).  
 
The two most commonly cited predictive studies were conducted in referral centres in France 
and Belgium, reflecting similar populations to our tertiary IBD clinic. In the French Saint-
Antoine hospital study of 1188 subjects (Beaugerie et al.2006), the term ‘disabling CD’ 
(DCD) encompassed several clinical scenarios within five years of diagnosis; ‘the presence of 
chronic debilitating symptoms, more than two courses of steroids (or steroid dependency), 
creation of a definitive stoma, further hospitalisation after diagnosis for flare-up or 
complications of the disease, the need for IMMs, surgery for perianal disease or bowel 
resection’. In this study, factors at diagnosis that were associated with the development of 
DCD were the need for corticosteroids (OR: 3.1, 95% CI: 2.2-4.4), an age below 40 years 
(OR: 2.1, 95% CI: 1.3-3.6), and the presence of perianal disease (OR: 1.8, 95% CI: 1.2-2.8). 
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The Positive Predictive Value of DCD in patients with 2 and 3 of these predictive factors was 
0.91 and 0.93, respectively. 
 
The definition of poor outcome CD used for this analysis has however been criticised as 
being too broad and as such the second Belgian study of 361 patients (while validating some 
predictors from the above study using the same definition of DCD described previously) also 
used a second, more rigid definition (Loly et al. 2008). Here, severe CD (SCD) was defined 
as ‘at least two small bowel resections or a small bowel resection of more than 50cm, any 
colonic resection, a definitive stoma or the development of complex perianal disease at any 
point during follow up’. Confirming the results of the study by Beaugerie et al (2006), 
perianal lesions and the need for steroids to treat the first flare, but not age below 40 years, 
were confirmed as predictive markers for developing DCD at five years. In addition 
ileocolonic location was a predictor of DCD, a finding also seen on univariate analysis in the 
Saint-Antoine cohort. Data analysis using the definition of SCD as the outcome, identified 
stricturing behaviour (HR: 2.1, 95% CI: 1.4-3.2) and weight loss > 5 kg (HR: 1.7, 95% CI: 
1.4-2.5) at diagnosis as factors independently associated with the time to development of 
SCD. 
 
Several other studies have confirmed clinical factors at diagnosis as predictors of poor 
outcome CD. In the prospective 10-year IBSEN follow-up study (Solberg et al. 2007) small 
bowel location, stricturing disease, penetrating behaviour and age younger than 40 were all 
found to be to be independent risk factors for future operative intervention. Upper GIT 
involvement has also been shown to predict poor outcome CD (Chow et al. 2009).Cigarette 
smoking is an environmental factor known to impact negatively on CD course and is 
associated with penetrating intestinal complications and the development of fistulas (Latakos 
et al. 2007; Rubin et al. 2000).  
 
There are also several laboratory-based predictors of poor outcome CD that have been 
evaluated. Notably, a number of antibodies against microbial antigens have been described in 
CD. The most studied are anti–Saccharomyces cerevisiae antibody (ASCA), antibody to the 
outer membrane porin of Escherichia coli (anti-OmpC) and antibody against flagellin 
expressed by Clostridia (anti-CBir1). High titres of these serum antibodies (ASCA, anti-
OmpC, and anti-CBir1) correlate with adverse CD outcomes (Vasiliauskas et al. 2000; Mow 
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et al. 2004). Finally, the presence of granulomas on histopathology and mutations of certain 
genes, notably the nucleotide-binding oligomerization (NOD2) gene are also markers of 
aggressive CD (Heresbach et al. 2005; Yarur et al. 2011). More recently gene expression 
profiling of CD8+ T cells was shown to predict a severe course of CD (Lee, et al. 2011). In 
this study there was a substantially increased risk of having f relapsing disease in those 
patients with increased expression of genes involved in antigen-dependent T cell responses. 
At present clinical predictors remain the best studied risk factors to guide therapeutic decision 
making, however it is likely in the future that combinations of both clinical and non-clinical 
features will allow better prognostication of severe disease. Recently Siegel and colleagues 
developed a model using system dynamics analysis (SDA) to assess the probability of 
developing a CD-related complication (Siegel, et al. 2011). This model included patient and 
disease variables, serological markers and medical therapies. Using SDA and Cox analyses 
they demonstrated how data can be transformed into a simple graph displaying a real-time 
individualised probability of disease complications and treatment response. 
 
Recently predictors of 15-year CD course were characterized in 600 patients, again from the 
Saint-Antoine cohort (Cosnes et al. 2011). Non-severe evolution was defined as ‘clinically 
inactive disease for greater than 12 years, less than one intestinal resection without permanent 
stoma and no death’. Factors independently associated with a non-severe 15-year clinical 
course were non-smoking status, rectal sparing, high educational level, older age and longer 
disease duration.  
5.0 The value of predicting disease course in CD 
 
The clinical presentation and course of CD progression is markedly heterogeneous; some 
patients rapidly developing severe, complicated disease, while others have a benign and 
uncomplicated path. Predicting which patients are at risk for progression to complications, 
and at what speed, has important implications. Firstly, an accurate prediction will aid in 
counselling patients and their families on future disease course. Secondly, it is useful in terms 
of treatment choices as the heterogeneity of CD requires a personalised, tailored approach 
(Louis et al. 2009; Yarur et al. 2011). It would be easier to implement aggressive treatment 
strategies and accept the associated risks if appropriate patients could be identified.  
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6.0 The value of treating early CD aggressively 
 
There is an emerging body of evidence to suggest that early treatment with IMMs and/or anti-
TNFs may modify the natural history of CD. Early use of intensive therapy is often referred 
to as the top-down (TD) strategy of treatment. This is contrasted with the traditional step-up 
(SU) strategy where these drugs are only introduced late in the course of the disease when 
other therapies such as corticosteroids and 5-aminocalicylates have failed (D’ Haens et al. 
2008). Unfortunately, traditional SU algorithms have not impacted the progressive nature of 
CD to any great extent, and the failure of traditional approaches to alter natural history can in 
part be attributed to their delayed introduction in advanced disease when complications are 
already irreversible (Cosnes et al. 2005). In contrast a TD approach (or at the very least an 
accelerated SU strategy) with the early and aggressive use of biologics, with or without 
IMMS, has been shown to be associated with better clinical outcomes, corticosteroid-free 
remission rates and the development of fewer complications, hospitalisations and surgical 
interventions (Colombel et al. 2010; D’ Haens et al. 2008; Feagan et al. 2008; Lichtenstein et 
al. 2005). In addition, this strategy is associated with superior endoscopic mucosal healing 
rates, an outcome which is rapidly becoming a surrogate marker for improving long-term 
outcomes and is increasingly used in clinical practice (D’ Haens et al. 2008).  
7.0 The potential risks of treating early CD aggressively 
 
In contrast to referral centre studies, analysis of population based cohorts suggests that a 
sizable subset of CD will run a benign course and never require corticosteroids or surgery 
(Munkholm et al. 1995). To subject these individuals to potentially toxic IMMs or biologic 
therapies would expose them to unnecessary risk. Thiopurine drugs (azathioprine and 6-
mercaptopurine) predispose to serious and opportunistic infections, as well as other possible 
side effects such as myelotoxicity, hepatotoxicity and pancreatitis. In addition, thiopurine use 
carries a risk of lymphoma (Kandiel et al. 2005; Siegel et al. 2009). Another commonly used 
IMM methotrexate may cause irreversible liver or lung fibrosis, while the anti-TNFs have 
been associated with an increased risk of infection, notably in our setting tuberculosis. 
Furthermore, using combinations of these potent therapies increases the potential for 
complications (Toruner et al. 2008). As a result, the early and aggressive use of these drugs 
in inappropriate patients who will likely experience a benign course of CD imparts 
unacceptable risk. 
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8.0 Individual markers to predict the course of CD 
 
Many different demographic, clinical, endoscopic, histologic, serologic, and genetic markers 
have been evaluated in predicting CD outcomes. Those for which there is evidence 
demonstrating a role in predicting poor outcome CD will be discussed. These predictors are 
summarised in Appendix 5. 
8.0 Clinical Markers predicting disease course in CD 
8.1 Age 
 Clinical and population-based studies have shown that patients diagnosed with CD at a 
younger age (<40 years) tend to have more aggressive CD (Beaugerie et al. 2006; Solberg et 
al. 2007). Young age is also associated with increased risk of surgery and disease recurrence 
(Romberg-Camps et al. 2009). 
8.2 CD behaviour 
Perianal disease has emerged as a strong predictor of poor outcome CD in most publications 
addressing this issue, regardless of how this endpoint was defined (Beugerie et al. 2006; 
Louis et al. 2009; Mekhjian et al.1979). In a Belgian cohort perianal disease was the 
strongest predictor of severe disease in patients with uncomplicated CD at diagnosis (Loly et 
al. 2008). Moreover perianal disease at diagnosis has been shown to confer a significant risk 
of developing DCD during 5 years of follow up (Beugerie et al. 2006), as well as being a 
significant predictor of change in CD behaviour (Tarrant et al. 2009). Stricturing disease at 
diagnosis has also been noted to be a marker of progression to SCD (Loly et al. 2008) and 
subsequent surgery (Solberg et al. 2007; Romberg-Camps et al. 2009). Penetrating disease 
behaviour is an additional risk factor predicting a more severe course of CD and the need for 
surgical intervention (Solberg et al. 2007). 
8.3 CD Location 
When compared to patients with ileal or ileocolonic involvement, patients with CD that is 
limited to the colon have a lower rate of surgery and are less likely to progress to complicated 
disease (Solberg et al. 2007; Thia et al. 2010). Similar findings were reported by Romberg-
Camps et al. (2009) in that small bowel location was a predictor of future surgery in their 
long term follow-up study. In addition, a recent study from New Zealand (Tarrant et al. 2009) 
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showed that progression towards complicated disease was more rapid in those with small 
bowel than colonic disease location. An Asian study (Chow et al. 2009) showed that 
involvement of the upper gastrointestinal tract was an independent predictor of more 
complicated disease, including hospitalisations.  
8.4 Corticosteroids 
Patients who require corticosteroid therapy during their first CD flare are more likely to 
develop DCD during 5 years of follow-up (Beaugerie et al. 2006). This was confirmed in 
another study addressing this same endpoint (Loly et al. 2008). 
 
 
8.5 Smoking 
An association between cigarette smoking and CD has long been recognised in that both 
current and former smoking (and possibly passive smoke exposure during childhood) 
increases the risk of CD almost 2-fold. In addition, current smoking has been shown to alter 
the disease course in that smokers with CD are more likely to run a complicated course, to 
develop stricturing or penetrating disease, to have ileal involvement and to undergo surgery. 
Smokers with CD also have higher steroid and more immunosuppressant requirements than 
non-smokers (Latakos et al. 2007; Rubin et al. 2000). 
8.6 Appendicectomy  
Studies exploring the association between appendicetomy and CD have reported conflicting 
findings. A recent meta-analysis demonstrated a significantly increased risk of developing 
CD within four years following this procedure. This risk diminished to baseline after five 
years, possibly reflecting misdiagnosis of early CD (Kaplan et al. 2008). The effect of a 
previous appendicectomy on disease course is also controversial with some but not all studies 
reporting an increased risk for surgical resection and more severe disease when compared to 
patients who had not undergone appendicetomy (Kaplan et al. 2007; Riegler et al. 2005). 
9.0 Histopathological markers predicting outcome in CD 
9.1 Epithelioid granuloma 
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Epithelioid granulomas are considered a histological characteristic of CD, however in reality 
only a minority of patients will have them on biopsy specimens. The presence of granulomas 
has been linked to a more complicated disease course with more extensive ileocolonic and 
upper gastrointestinal tract involvement and penetrating disease (Freeman 2007). In addition 
the presence of granulomas may independently predict the need for surgical resection 
(Heresbach et al. 2005). 
9.2 Inflammatory Markers 
The most commonly used surrogate marker of inflammation in CD is the C-reactive protein 
(CRP). A rise in CRP often heralds a flare-up of disease and patients with higher levels are 
more likely to relapse and require corticosteroids (Consigny et al. 2006). Although this test is 
simple to perform, readily available and valuable in assessing inflammatory activity, CRP 
values have not proven to be good predictors of poor outcome CD. In one Norwegian study 
(Henriksen et al. 2008) there was no association between CRP levels at diagnosis and 
subsequent risk of surgery. However, in this study a significant association was noted for 
CRP levels above 53 mg/l in a small sub-group with isolated ileal involvement (OR 6.0, 95% 
CI 1.1 to 31.9, p = 0.03). 
9.3 Serological markers 
Several studies have shown that serological markers such as ASCA, anti-OmpC and cBir1 
antibodies predict CD complications and the need for surgery (Vasiliauskas et al. 2000; Mow 
et al 2004). ASCA in particular has been associated with penetrating disease and early need 
for surgery. In addition the number and level of antibody response (ASCA, anti-OmpC, and 
anti-CBir1) correlated with internal penetrating and stricturing disease and the need for 
surgery in a large paediatric CD cohort (Dubinsky et al. 2008). 
9.4 Genetic markers 
The most studied susceptibility gene in CD is that of the nucleotide-binding oligomerisation 
domain 2 (NOD2). Several common mutations in this gene confer an increased risk of 
developing CD and have been found to predict the development of small bowel strictures and 
the need for early surgery. A recent meta-analysis of 49 studies (Adler J, et al. 2011) showed 
that the presence of a single NOD2 mutation predicted an 8% increase in the risk for 
complicated disease (B2 or B3), whereas 2 mutations conferred a 41% increase. NOD2 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
27 
 
mutations did not predict perianal disease (P = 0.4) but were associated with the need for 
surgery (RR 1.6, 95% CI 1.4 – 1.8, P < 0.001). Unfortunately the predictive power associated 
with a single NOD2 mutation was weak, but the presence of two NOD2 mutations had 98% 
specificity for complicated disease (although sensitivity was poor at 11%). Besides NOD2 
other CD susceptibility genes have also been evaluated as prognosticators of poor outcome. 
Recently a large Dutch study (Weersma et al. 2009) evaluated several CD genes; NOD2, the 
IBD5 locus, the Drosophila discs large homologue 5 (DLG5), autophagy-related 16-like 1 
(ARG16L1) and the interleukin 23 receptor (IL23R) genes. The authors demonstrated that 
patients with a severe course of CD had more risk alleles (p = 0.0008) compared to patients 
with uncomplicated behaviour (Weersma et al. 2009). 
 
9.5 Endoscopic markers 
In a French study of CD (Allez et al. 2002) with a median follow up of 52 months it was 
shown that the presence of deep and extensive colonic ulceration was associated with a high 
risk of colectomy.  
9.6 Summary  
The ability to predict which patients will develop poor outcome CD and thereby target these 
individuals with early and aggressive medical therapies would be of great value. An 
increasing wealth of data has emerged in recent years on predicting prognosis in patients with 
CD, with a number of clinical, serologic, endoscopic and genetic markers showing promise. 
Clinical factors, in particular perianal disease and ileal location at diagnosis, seem to be the 
simplest and most useful to date.  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
28 
 
References 
 
Allez M, Lemann M, Bonnet et al. (2002) Long term outcome of patients with active Crohn’s 
disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 
97: 947-953 
Adler J, Rangwalla SC, Dwamena BA et al. (2011) The prognostic power of the NOD2 
genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol 
106:699-712 
Beaugerie L, Seksik P, Nion-Larmurier I et al. (2006) Predictors of Crohn’s disease. 
Gastroenterology 130:650-656 
Chow DK, Sung JJ, Wu JC, et al. (2009) Upper gastrointestinal tract phenotype of Crohn’s 
disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis 
15:551-557 
Colombel JF, Sandborn WJ, Reinisch W et al. (2010) Infliximab, azathioprine or 
combination therapy for Crohn’s disease. N Engl J Med 362:1383-1395 
Consigny Y, Modigliani R, Colombel JF et al. (2006) A simple biological score for 
predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 
12:551–557 
Cosnes J, Cattan S, Blain A et al. (2002) Long-term evolution of disease behaviour of 
Crohn’s disease. Inflamm Bowel Dis 8:244-250 
Cosnes J, Gower-Rousseau C, Seksik P et al. (2011) Epidemiology and natural history of 
inflammatory bowel diseases. Gastroenterology 140:1785-94 
Cosnes J, Nion-Larmurier I, Beaugerie L et al. (2005) Impact of the increasing use of 
immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 54:237-
241 
D’Haens G, Baert F, van Assche G et al. (2008) Early combined immunosuppression or 
conventional management in patients with newly diagnosed Crohn’s disease: an open 
randomised trial. Lancet 371:660-667 
Dubinsky M.C, Kugathasan S, Mei L et al. (2008) Increased immune reactivity predicts 
aggressive complicating Crohn’s disease in children. Clin Gastroenterol Hepato 
6:1105-1111 
Feagan B, Panaccione R, Sandborn WJ et al. (2008) Effects of adalimumab therapy on 
incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM 
study. Gastroenterology 135:1493-1499 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
29 
 
Freeman HJ. Granuloma-positive Crohn’s disease. (2007) Can J Gastroenterol 21:583-587 
Hellers G, Bergstrand O, Ewerth S et al. (1980) Occurrence and outcome after primary 
treatment of anal fistulae in Crohn’s disease. Gut 21:525-527 
Henriksen M, Jahnsen J, Lygren I et al. (2008) C-reactive protein: a predictive factor and 
marker of inflammation in inflammatory bowel disease. Results from a prospective 
population-based study. Gut 57:1518-1523  
Heresbach D, Alexandre JL, Branger B et al. (2005) Frequency and significance of 
granulomas in a cohort of incident cases of Crohn’s disease. Gut 54:215-222 
Kandiel A, Fraser AG, Korelitz BI et al. (2005) Increased risk of lymphoma among 
inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. 
Gut 54: 1121-1125  
Kaplan GG, Pedersen BV, Andersson RE, et al. (2007) The risk of developing Crohn’s 
disease after an appendectomy: a population-based cohort study in Sweden and 
Denmark. Gut 56:1387-1392. 
Kaplan GG, Jackson T, Sands BE et al. (2008) The risk of developing Crohn’s disease after 
an appendectomy: a meta-analysis. Am J Gastroenterol 103:2925–2931 
Lakatos PL, Szamosi T, Lakatos L. (2007) Smoking in inflammatory bowel diseases: good, 
bad or ugly? World J Gastroenterol 13:6134-6139  
Lee JC, Lyons PA, McKinney EF, et al. (2011) Gene expression profiling of CD8+ T cells 
predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin 
Invest.121:4170-9 
Lichtenstein GR, Yan S, Bala M et al. (2005) Infliximab maintenance treatment reduces 
hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. 
Gastroenterology 128:862-869  
Lichtenstein GR, Feagan BG, Cohen RD et al. (2006) Serious infections and mortality in 
association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol 
Hepatol 4:621-630 
Loly C, Belaiche J, Louis E. (2008) Predictors of severe Crohn’s disease. Scand J 
Gastroenterol 43:948-954 
Louis E, Colard A, Oger AF et al. (2001) Behaviour of Crohn’s disease according to the 
Vienna classification: changing pattern over the course of the disease. Gut 49:777-782 
Louis E, Michel V, Hugot JP et al. (2003) Early development of stricturing or penetrating 
pattern in Crohn’s disease is influenced by disease location, number of flares, and 
smoking but not by NOD2/CARD15 genotype. Gut 52:552-557 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
30 
 
Louis E, Belaiche J, Reenaers C. (2009) Tailoring the treatment to the individual in Crohn’s 
disease. Ther Adv Gastroenterol 2:239-244 
Mekhjian HS, Switz DM, Watts HD et al. (1979) National Cooperative Crohn’s Disease 
Study: factors determining recurrence of Crohn’s disease after surgery. 
Gastroenterology 77:907-913 
Mow W, Vasiliauskas E, Lin Y et al. (2004) Association of antibody responses to microbial 
antigens and complications of small bowel Crohn’s disease. Gastroenterology 126:414-
424 
Munkholm P, Langholz E, Davidsen M et al. (1995) Disease activity courses in a regional 
cohort of Crohn’s disease patients. Scand J Gastroenterol 30: 99-706  
Riegler G, Caserta L, Esposito I et al. (2005) Worse clinical course of disease in Crohn’s 
patients with previous appendectomy. Eur J Gastroenterol Hepatol 17:623-627 
Romberg-Camps MJ, Dagnelie PC, Kester AD et al. (2009) Influence of phenotype at 
diagnosis and of other potential prognostic factors on the course of inflammatory bowel 
disease. Am J Gastroenterol 104:371-383 
Rubin DT, Hanauer SB. (2000) Smoking and inflammatory bowel disease. Eur J 
Gastroenterol Hepatol 12:855-862 
Siegel C, Marden S, Persing S et al. (2009) Risk of lymphoma associated with combination 
anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's 
disease: a meta-analysis. Clin Gastroenterol Hepatol 7:874-881 
Siegel CA, Siegel LS, Hyams JS et al. (2011) Real-time tool to display the predicted disease 
course and treatment response for children with Crohn's disease. Inflamm Bowel Dis. 
17:30-8 
Solberg IC, Vatn MH, Høie O et al. (2007) IBSEN Study Group. Clinical course in Crohn’s 
disease: results of a Norwegian population-based ten-year follow-up study. Clin 
Gastroenterol Hepatol 5:1430-1438 
Tarrant KM, Barclay ML, Frampton CM et al. (2008) Perianal disease predicts changes in 
Crohn's disease phenotype-results of a population-based study of inflammatory bowel 
disease phenotype. Am J Gastroenterol 103:3082-3093 
Thia KT, Sandborn WJ, Harmsen, et al.  (2010) Risk factors associated with progression to 
intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 
139:1147-55 
Toruner M, Loftus E, Harmsen W et al. (2008) Risk factors for opportunistic infections in 
patients with inflammatory bowel disease. Gastroenterology 134: 929-936  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
31 
 
Vasiliauskas EA, Kam L, Karp LC et al. (2000) Marker antibody expression stratifies 
Crohn’s disease into immunologically homogeneous subgroups with distinct clinical 
characteristics. Gut 47:487-496 
Weersma RK, Stokkers PC, van Bodegraven AA et al. (2009) Molecular prediction of 
disease risk and severity in a large Dutch Crohn’s disease cohort. Gut 58:388-395 
Wright JP, Froggatt J, O’Keefe EA et al. (1996) The epidemiology of inflammatory bowel 
disease in Cape Town 1980-1984. S Afr Med J 70:10–15  
Yarur AJ, Strobel SG, Deshpande AR et al. (2011) Predictors of aggressive inflammatory 
bowel disease. Gastroenterol Hepatol 7:652-659 
Part C: Journal “ready” manuscript for submission to the South 
African Medical Journal 
(Instructions for authors are recorded in Appendix 2. As per these instructions references are 
in the Vancouver style, thus differing from Part A and B) 
 
Abstract 
 
Background and aims 
 
The majority of patients with Crohn's disease (CD) will develop complications in the form of 
strictures or fistulas over time, impacting negatively on quality of life and resulting in 
hospitalisations and surgery. Timely drug therapy with immunomodulators and biologics may 
alter this natural history but carries a significant risk of side-effects. The aim of our study was 
to indentify predictive factors at diagnosis for poor outcome CD in order to identify those 
who would most benefit from early, aggressive medical therapies.  
 
Methods 
 
This study included 120 CD patients (diagnosed 1980-2006), with follow-up exceeding 5 
years and complete data at baseline. Two different definitions of poor outcome CD were 
evaluated according to predefined criteria: disabling CD within five years of diagnoses 
(DCD) and severe CD over the entire disease course (SCD). Clinical, demographic, 
laboratory and biological factors associated with these outcomes were evaluated by univariate 
and multivariate analysis. 
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Results 
 
Seventy two percent (86/120) developed DCD within 5 years of diagnosis; on multivariate 
analysis perianal disease (OR 11.0, 95% CI 1.1-94.7, p=0.03) and ileal involvement at 
diagnosis (OR 5.4, 95% CI 2.1-13.9, p<0.001) were predictive. Overall 38% (45/120) 
developed SCD and on multivariate Cox proportional hazard analysis penetrating behaviour 
(HR 2.9, 95% CI 1.2-7.0, p=0.02), stricturing behaviour (HR 4.6, 95% CI 1.5-14.6, p=0.01), 
perianal disease (HR 3.4, 95% CI 1.6-7.2, p=0.01) and the presence of biopsy granulomas 
(HR 2.4, 95% CI 1.3-4.6, p=0.01) at diagnosis were independently associated with time to the 
development of SCD. When analysis was restricted to non-stricturing and non-penetrating 
disease, perianal CD and tissue granulomas remained strongly associated with the 
development of SCD. These 2 risk factors yielded a specificity of 99% and a positive 
predictive value of 89%. 
 
Conclusion 
 
At the time of diagnosis, factors predictive of subsequent SCD in our referral centre were 
stricturing or penetrating phenotype, perianal disease and tissue granulomas. 
1.0 Introduction 
 
Crohn’s disease (CD) is a chronic disorder with variable clinical manifestations and a 
heterogeneous disease course. The phenotype of CD is defined by age at diagnosis, location 
of disease and disease behaviour according to the Montreal classification.
1
 Behaviour is sub-
divided into ‘non-stricturing and non-penetrating’ (B1), ‘stricturing’ (B2) and ‘penetrating’ 
(B3) disease. The behaviour of CD tends to evolve over time to be complicated by the 
development of strictures, fistulas or abscesses. At diagnosis more than 80% of patients have 
purely inflammatory B1 luminal disease, but by 10 years more than half will have progressed 
to complicated stenosing (B2) and penetrating (B3) phenotypes, often requiring 
hospitalisation.
2,3
 Ultimately 80% will undergo surgery.
4
  
 
Early and aggressive medical therapy with immunomodulators (IMMS) and biologics may 
alter this natural history and improve long-term outcomes.  However, such strategies place 
patients at risk of adverse events such as infections and malignancy.
5,6
 In addition, population 
based studies have shown that a sizable number of CD patients will have a benign course, 
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never require surgery and never suffer a flare-up severe enough to warrant corticosteroids.
7
 
To subject these individuals to drugs with potentially serious side effects is unacceptable. In 
addition these medications (notably biologics) are expensive and access is limited in resource 
challenged environments such as ours.  
 
Recently, several studies have analysed factors early in the course of CD which may predict 
future outcomes and identify those patients at risk of developing complicated CD who would 
receive greatest benefit from early, aggressive therapy. Equally importantly these factors 
could identify people who will most likely have a benign course of CD, so as to avoid 
subjecting them to potentially toxic therapies. In a seminal French study by Beaugerie et al. 
(2006), an initial need for corticosteroids (OR: 3.1, 95% CI: 2.2-4.4), an age below 40 years 
(OR: 2.1, 95% CI: 1.3-3.6), and the presence of perianal disease (OR 1.8, 95% CI: 1.2-2.8) at 
diagnosis were associated with the development of disabling CD (DCD) within five years.
8
 
The positive predictive value of two or three of these risk factors was 0.91 and 0.93 
respectively. A subsequent Belgian study by Loly et al. (2008) designed to validate these 
findings confirmed that perianal lesions at diagnosis and the need for steroids to treat the first 
flare (but not age below 40 years) were predictive markers for DCD. In addition they 
demonstrated that ileocolonic location was also associated with DCD (OR 1.74, 95% CI 1.06-
2.8). 
9 
 
The definition of poor outcome DCD used in these studies has however been criticized as 
being too broad and as a consequence three-quarters of study patients had disabling disease, a 
sub-group too large to target with aggressive medical therapies. As a result Loly et al. (2008) 
used a second, more restrictive definition of severe CD (SCD) which reflected ‘clinically 
significant, non-reversible GIT damage over the entire disease course, characterised by the 
development of complex perianal disease, any colonic resection, two or more small-bowel 
resections, a single small-bowel resection of greater than 50 cm or the construction of a 
definitive stoma’.9 The rate of SCD using this definition was 37.4%. Stricturing behaviour 
(HR: 2.1, 95% CI: 1.4-3.2) and weight loss exceeding 5kgs (HR: 1.7, 95% CI: 1.1-2.5) at 
diagnosis were independently associated with the time to development of SCD. 
 
To date no study has been done in South Africa to analyse risk factors at diagnosis predicting 
the subsequent development of poor outcome CD. It is unclear if these forementioned 
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predictive variables from French and Belgian populations are applicable in our local setting 
given that our patients differ from those treated in the West. Notably common genetic CD-
susceptibility mutations seen frequently in the developed world are not a feature of CD in our 
clinic population.
10
 In light of the potential risk of progression to complicated CD over time, 
and the lack of local evidence regarding which patients are at risk, the aim of this study was 
to evaluate the association between clinical and laboratory indices at the time of first 
diagnosis and subsequent adverse disease outcomes among CD patients receiving care at a 
tertiary hospital in Cape Town. 
2.0 Methods 
 
Patient eligibility 
The protocol was approved by the Ethics Committee of the University of Cape Town. Of 567 
CD patients registered in our database (up to 31
st
 December 2011) 310 had duration of CD 
exceeding 5 years. We reviewed the clinical notes of these patients. Patients were excluded if 
there was incomplete data at baseline, if the initial diagnosis had been subsequently revised, 
if they had not been seen at the clinic within the preceding year, if there was complex 
perianal disease at diagnosis or if they had undergone surgical resection within one month of 
diagnosis. The vast majority of exclusions (80%) were due to missing or unreadable notes or 
microfilms from the time of initial diagnosis. Details of those excluded are listed in Appendix 
4. One hundred and twenty patients were eligible for inclusion. 
 
Study design 
 
This was a retrospective cohort study. Two different definitions of poor outcome CD were 
evaluated according to predefined criteria: 
 
DCD (as defined by Beaugerie et al. 2006)
 8
: ‘when within five years at least one of the 
following criteria is present  
1. More than two steroid courses required and/or dependence on steroids 
2. Further hospitalisation after diagnosis for flare-up or complications of the disease 
3. Presence of disabling chronic symptoms (cumulative time of more than 12 months of  
disabling symptoms: diarrhoea with nocturnal and/ or urgent stools, intense 
abdominal pain or extra-intestinal manifestations) 
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4. The need for IMMs 
5. Intestinal resection or surgery for perianal disease 
SCD (as defined by Lolly et al) 
9
: ‘any one of the following over the entire disease course 
1. The development of  complex perianal disease 
2. Any colonic resection 
3. Two or more small-bowel resections 
4. A single small-bowel resection measuring more than 50 cm in length 
5. The construction of a definitive stoma’ 
 
Our specific objectives were three-fold: 
1. To validate clinical factors at first diagnosis of CD previously shown in French and 
Belgian populations to be predictive of DCD within five years. 
2. To explore the association between additional clinical, biochemical and histological 
factors at diagnosis and the development of DCD within five years of diagnosis. 
3. To explore the association between additional clinical, biochemical and histological 
factors at diagnosis and time to the development of SCD over the entire disease 
course 
 
Patients were followed-up from the time of CD diagnosis until the 31
st
 of December 2011 or 
alternatively until the development of predefined endpoints of DCD or SCD or date of death. 
The following data was collected and recorded on an Excel spreadsheet. 
 
Demographics: age, gender, race, date of CD diagnosis, duration of follow-up 
 
Clinical factors at diagnosis: disease location (as per the Montreal classification), extent of 
small bowel involvement (in centimetres), number of colonic segments involved (ascending 
colon, transverse colon, descending colon, sigmoid colon and rectum, maximum of five), 
corticosteroid use, family history of IBD, history of appendicectomy, smoking status (patients 
were considered current smokers if ≥ 7 cigarettes per week, disease behaviour (as per the 
Montreal classification)  
 
Biochemical factors at diagnosis: haemoglobin, white cell count, platelet count, C- reactive 
protein (CRP), and albumin.  These markers were considered as normal or abnormal 
according to the reference range 
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Histology at diagnosis: the presence or absence of tissue granulomas 
 
Within five years of diagnosis: further corticosteroid use after diagnosis, further 
hospitalisation after diagnosis, surgery, creation of a definitive stoma, progression from B1 to 
B2 or B3 phenotypes (as per the Montreal classification), IMM use, biologic use 
 
Over the entire disease course: surgical resections, the development of complex perianal 
fistulas, and creation of a definitive stoma 
3.0 Statistical analysis 
 
 For the first part of the study the association between all baseline risk factors and the 
development of DCD within five years of diagnosis was assessed by univariate analysis. All 
continuous variables evaluated were not normally distributed and are thus expressed as 
medians and interquartile ranges (IQR). Categorical variables were compared using the Chi2 
or the Fisher exact test when appropriate. Those variables with P values below 0.10 were 
further tested in a series of logistic multivariate regression models. For the second part of the 
study univariate and multivariate Cox proportional hazard analysis was used to identify risk 
factors at diagnosis that were associated with time to the development of SCD during follow-
up. The proportional hazards assumption for specific predictor variables was checked and a 
departure from this assumption was not noted for any of the predictor variables. The Kaplan-
Meier method was used to estimate the cumulative probability (1 minus survival-free) of 
SCD as well as progression from B1 to B2 or B3 phenotypes over time. 
4.0 Results 
 
The case records of patients diagnosed with CD at Groote Schuur Hospital between 1980 and 
31
st
 December 2006 were retrospectively reviewed. Overall 120 were deemed eligible for 
study inclusion. Sixty percent (72/120) of the cohort were female. The median age at 
diagnosis was 31 years (IQR 23-40). The majority of study participants were of ‘cape 
coloured’ ancestry (76%, 91/120), 18% (22/120) were caucasian and 6% (7/120) black. At 
diagnosis 40 % (48/120) had isolated ileocaecal (L1) disease, 26% (31/120) isolated colonic 
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(L2) disease and 34% ileocolonic (L3) disease (41/120). Five percent (6/120) also had 
involvement of the upper GIT. At diagnosis disease behaviour was classified as non-
stricturing, non-penetrating (B1) in 84% (101/120), stricturing (B2) in 6% (7/120) and 
penetrating (B3) in 10% (12/120). Thirteen percent (16/120) had evidence of perianal disease. 
Sixty five percent (78/120) were active cigarette smokers at the time of diagnosis. Fifty four 
percent (65/120) were treated with corticosteroids for the first flare of disease. 
 
The development of DCD 
Overall 72% (86/120) developed DCD within five years of diagnosis. The median time to the 
development of DCD was 12 months (IQR 5-24). Univariate analysis of all baseline 
parameters was performed and the results of these are presented in Tables 1 and 2.  
At diagnosis the presence of perianal disease, a history of more than five kilogram weight 
loss and small bowel involvement exceeding 20cm were significantly associated with the 
development of DCD within five years. Isolated colonic involvement at diagnosis (L2) 
appeared to confer protection against developing DCD when compared to other locations (L1 
or L3). In contrast, age at diagnosis, smoking status, use of steroids for the 1
st
 flare and 
disease behaviour were not significantly associated with the development of DCD. None of 
the laboratory or histological parameters evaluated at diagnosis predicted the development of 
DCD within five years. On multivariate analysis only perianal disease (OR 11.0, 95% CI 1.1-
94.7, p=0.03) and ileal (L1 or L3) involvement at diagnosis (OR 5.4, 95% CI 2.1-13.9, 
p<0.001) were significantly associated with the development of DCD within five years. 
Sensitivity, specificity, pos tive predictive value (PPV) and negative predictive value (NPV) 
of the model including these two risk factors were 90%, 47%, 81% and 64%, respectively. 
The area under the receiver operating characteristic (ROC) curve was 0.72. 
 
The development of SCD 
Overall 38% (45/120) of patients developed SCD over their disease course. The median time 
to the development of SCD was 36 months (IQR 11-76). The Kaplan-Meier method was used 
to calculate the cumulative probability of SCD, which was 11.7%, 25.3% and 35.1% at 1, 5, 
and 10 years after diagnosis respectively. Kaplan-Meier curves for the development of SCD 
are shown in Figure 1. Clinical, laboratory and histological predictors at diagnosis associated 
with the time to development of SCD are presented in Tables 3 and 4. After multivariate 
analysis, only penetrating disease behaviour (HR2.9, 95% CI 1.2-7.0, p=0.02), stricturing 
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disease behaviour (HR 4.6, 95% CI 1.5-14.6, p=0.01), perianal disease (HR 3.4, 95% CI 1.6-
7.2, p=0.01) and the presence of granulomas (HR 2.4, 95% CI 1.3-4.6, p=0.01) at diagnosis 
were independently associated with time to the development of SCD.  
 
B1 disease at diagnosis 
Overall 34% (34/101) of patients with purely B1 phenotype at diagnosis developed SCD. The 
median time to the development of SCD was 43 months (IQR 11-96). On multivariate Cox 
analysis risk factors at diagnosis that were significantly associated with time to the 
development of SCD were perianal disease (HR 2.8, 95% CI 1.3-6.0, p= 0.01) and the 
presence of tissue granulomas (HR 2.2, 95% CI 1.1-4.4, p= 0.03).  
 
Kaplan-Meier curves for the development of SCD according to the presence or absence of 
these 2 factors are shown in Figure 2. Sensitivity, specificity, PPV and NPV of a logistic 
regression model including these two risk factors were 21%, 99% and 88% and 71%, 
respectively. The area under the ROC curve was 0.68. 
 
Overall 43% (43/101) patients with B1 disease at diagnosis progressed to B2 or B3 
phenotype over time. The cumulative probability of developing either of these was 13% at 
1year, 24% at 2 years, 33% at 5 years, 43% at 10 years and 68% at 20 years. The median time 
to progression was 24 months (IQR 11-78). None of the baseline parameters assessed was 
significantly associated with time to B2/B3 progression. 
 
Forty patients (40%) with B1 phenotype at diagnosis ultimately required a surgical resection, 
while 26 (26%) underwent 2 or more surgical resections. Granulomas at diagnosis was the 
only predictor for more than one surgical procedure during follow up (OR 4.7; 95% CI 1.8-
12.3, p=0.002). 
5.0 Discussion 
 
Our results are consistent with previous reports in that the majority of CD patients had 
uncomplicated non-penetrating, non-stricturing CD at initial diagnosis and the majority went 
on to a disabling disease course over time. Seventy two percent of our cohort developed DCD 
within 5 years of diagnosis, similar to the 85.2% and 57.9% reported by Beaugerie et al and 
Loly et al respectively.
8,9
 As was shown in their studies the presence of perianal lesions at 
baseline was predictive. However other variables such as the need for corticosteroids for the 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
39 
 
first flare and age less than 40 years were not shown to be associated with an increased risk in 
our cohort. This may reflect our much smaller sample size then those in the forementioned 
studies. We also showed that ileal involvement at diagnosis is predictive of DCD while 
isolated colonic disease is protective. This concurs with data from the large population-based 
IBSEN Scandinavian cohort study which showed that ileal location was associated with 
future surgical resection, a finding validated in a Maastricht population-based cohort.
11,12
  In 
addition, a study from New Zealand has shown that progression towards complicated disease 
was more rapid in those with small bowel than colonic disease location (P < 0.001).
13 
 
The very high proportion of patients developing DCD in our study echoes the loose definition 
of this outcome, making it somewhat impractical in guiding therapeutic decision-making. The 
more restrictive end-point of SCD defined by Loly et al., reflecting non-reversible and 
clinically significant damage, is likely to be more meaningful in assessing the risks and 
benefits of early, aggressive therapy.
9
 Overall 38% of our cohort developed SCD over their 
disease course. This is almost identical to that reported by Loly et al. in their Liège cohort.
9  
We found that perianal disease, penetrating or stricturing behaviour and granulomas at 
diagnosis were associated with earlier development of SCD. Several publications have also 
identified stricturing or penetrating CD phen type at diagnosis as predictors of poor outcome. 
Loly et al. showed a strong association between stricturing disease at diagnosis and time to 
development of SCD (HR: 2.1, 95% CI: 1.4-3.2).
9
 In the previously mentioned Maastricht 
cohort, stricturing lesions were predictive of first surgery in 476 patients with a mean follow-
up of 7 years, a finding also noted in the IBSEN study.
11,12  
In addition the IBSEN data 
showed an association between penetrating disease and time to first surgery.
12 
 
When considering our patients with uncomplicated non-stricturing, non-penetrating disease 
(B1) at diagnosis, perianal lesions and granulomas were again associated with an 
unfavourable outcome. Perianal disease has emerged as a strong predictor of poor outcome 
CD in most publications addressing this issue, regardless of how this endpoint was defined. 
In the study by Loly et al. perianal disease was the strongest predictor of SCD in patients 
with uncomplicated disease at diagnosis.
9
 The previously mentioned New Zealand study also 
showed that perianal disease was a significant predictor of change in CD behaviour over time 
(HR: 1.62, P < 0.001).
13 
It is unclear how perianal disease may predispose to poor-outcome 
CD but this association may reflect a genetic susceptibility. Recently an Italian study has 
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shown an association between polymorphisms in a known CD susceptibility gene, the IRGM 
(immunity-related GTPase) gene, and the risk of perianal fistulising CD.
20
 Polymorphisms in 
this gene also predicted the development complicated CD.
20
 
Epithelioid granulomas are considered a histological characteristic of CD, however in reality 
only 15–25% of patients will have them on biopsy specimens and their pathogenesis is 
unknown. Only a few studies evaluating poor outcome CD have included granulomas in 
analysis. A study by Freeman showed that the presence of granulomas was linked to a more 
complicated disease course, with more extensive ileocolonic and upper gastrointestinal tract 
involvement and penetrating disease.
14
 In addition the presence of granulomas may 
independently predict the need for surgical resection
15
 and in our study granulomas at 
diagnosis was the only predictor for more than one surgical procedure during follow up. It is 
unclear how granulomas may influence CD outcome however one possible explanation is an 
association with autophagy genetic variants. Autophagy is a process involved in the 
elimination of intracellular bacteria and this pathway appears altered in CD. Reduced 
clearance of pathogenic bacteria might drive the chronic inflammation observed in these 
patients. Genetic variants in autophagy genes ATG16L1 (autophagy-related gene 16-like 1) 
and IRGM (immunity-related GTPase M) have been associated with susceptibility to CD. A 
recent study from Leuven evaluated surgical specimens from 464 CD patients and found 
associations between granulomas and several autophagy gene variants. In addition this study 
showed that granulomas were predictive of aggressive CD.
16
 
In contrast to our study findings, Loly et al. showed that weight loss exceeding five 
kilograms at diagnosis was a predictor of SCD. Interestingly when they restricted their 
analysis to patients with B1 disease at diagnosis this was no longer significant, suggesting 
that weight loss was associated with complicated CD at diagnosis and not a predictor of SCD 
in its own right.
9 
 
Our study has a number of limitations. Firstly, we excluded patients with missing or 
incomplete data at diagnosis. This accounted for 80% of exclusions and was largely due to 
missing or unreadable microfilms documenting the initial consultation, incomplete note 
taking by the diagnosing physician or unavailable blood results. As such baseline 
characteristics (to determine if they differed from study patients who were included) were 
difficult to obtain in these individuals. This is a potential source of bias; however it is likely 
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that this data was missing at random and not correlated with CD severity or outcome. In 
addition, the cumulative probabilities of progressing from B1 disease at diagnosis to 
stenosing or penetrating phenotypes over time is almost identical to those reported in a large 
population based study from Olmsted County, Minnesota.
17 
Furthermore, baseline 
demographics (age and gender) as well as disease location and behaviour of our study 
participants were very similar to that reported in a large New Zealand population-based CD 
cohort, with the exception that many more of our patients were active smokers at diagnosis.
13
 
Another potential source of bias is that only patients with complete follow up data were 
included. This could introduce selection bias as patients lost to follow up may have less 
severe disease than those who continued to be seen in our clinic. A further possible bias is 
that ours is a referral centre and our clinic patients may have more aggressive CD than those 
seen at other hospitals. However, the percentage of patients treated with corticosteroids for 
the first flare-up (54%) was very similar to that in a large North European population-based 
study.
7 
Another potential confounding factor in our study is the ethnic distribution of our 
cohort, which differs from that of the Western Cape population. In the 2011 national census 
48.8% of people in the Western Cape described themselves as ‘coloured’, 32.8% as ‘black’", 
15.7% as ‘white’", and 1.0% as ‘asian’. 21 In our cohort the vast majority (76%) of subjects 
were coloured. This notable difference from the demographics of the general population may 
reflect a discord in medical care provision as a consequence of the Apartheid system, 
whereby white South Africans had better access than other racial groups to private health 
care; resulting in the majority of patients attending state institutions such as ours being of 
non-white ethnicity. An additional study limitation is that we did not evaluate serological, 
endoscopic or genetic predictors of poor outcome as these are not routinely tested in our 
clinic. Finally our study population was relatively small and could have been underpowered 
to detect significant associations for some of the baseline factors which may be predictive of 
poor outcome CD. 
 
Despite these limitations our study has provided some valuable information, notably this is 
the first South African study to identify predictors of poor outcome CD. This will aid the 
decision in our setting when to risk aggressive medical therapies early in the disease course. 
As emphasised by Louis et al in a recent review there are two possible errors in managing 
CD: over treating patients who will have benign disease and under treating those who will go 
on to develop poor outcomes.
19
 Most patients who have stricturing or penetrating phenotypes 
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at diagnosis would already be considered complicated and thus candidates for aggressive 
therapy with IMMs and biologics.
18
 As such, predicting poor outcome CD in these patients is 
not as valuable as in patients with uncomplicated disease. Here, the decision to start disease 
modifying therapies has far more important consequences. In our study perianal disease and 
granulomas at diagnosis were very specific for the development of SCD over the disease 
course. Only 1% of individuals with these two predictors at diagnosis would be falsely 
classified as having SCD and thus subjected to aggressive therapies unnecessarily. In addition 
these two risk factors are routinely assessed at baseline and do not require expensive blood 
testing or genetic analysis. 
6.0 Conclusion 
 
Data from this retrospective study has shown that 72% of our cohort developed DCD within 
five years of diagnosis. This proportion is too high to use predictive factors at diagnosis to 
guide therapeutic algorithms. However using the more restrictive definition of SCD 38% of 
our cohort developed poor outcome CD over their disease course, a more clinically 
appropriate endpoint to target. Our study has identified several factors at diagnosis predictive 
of this outcome. Notably perianal disease and granulomas were independently associated 
with time to the development of SCD in patients with uncomplicated CD at diagnosis. The 
PPV of these two risk factors at diagnosis is 88% and the specificity 99%. 
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Table 1: Demographic and clinical predictors of DCD at diagnosis: univariate analysis 
Disease course within 5 years of diagnosis 
Predictors at diagnosis* Disabling CD 
N =86 (%) 
Non-disabling CD 
N =34 (%) 
p 
Female gender 49/86 (57%) 23/34 (68%) 0.28 
Race 
White 
Black 
Coloured 
 
15/86 (17%) 
5/86 (6%) 
66/86 (77%) 
 
7/34 (21%) 
2/34 (6%) 
25/34 (74%) 
 
0.92 
Age*  31 (23-38) 32 (24-41) 0.44 
Age 
A1, <17 
A2, 17-40 
A3, >40 
 
7/86 (8%) 
59/86 (69%) 
20/86 (23%) 
 
2/34 (6%) 
23/34 (68%) 
9/34 (26%) 
0.87 
Behaviour 
B1 
B2 
B3 
 
69/86 (80%) 
6/86 (7%) 
11/86 (13%) 
 
32/34 (94%) 
1/34 (3%) 
1/34 (3%) 
 
0.17 
Perianal disease 15/86 (17%) 1/34 (3%) 0.04 
Location 
L1 
L2 
L3 
 
39/86 (45%) 
15/86 (18%) 
32/86 (37%) 
 
9/34 (26%) 
16/34 (47%) 
9/34 (27%) 
 
0.004 
Extent of SB in cm* 
Extent of SB>20cm 
10 (5-20) 
28/86 (33%) 
5 (0-10) 
4/34 (12%) 
0.002 
0.02 
Number of colonic segments involved* 1 (0-3) 3 (0-4) 0.09 
Upper GIT involvement 4/86 (5%) 2/34 (6%) 0.55 
Rectal involvement  12/86 (14%) 7/34 (21%) 0.37 
IBD Family history   8/86 (9%) 3/34 (9%) 0.62 
Current smoker 58/86 (67%) 20/34 (59%) 0.37 
Past appendicectomy 9/86 (11%) 1/34 (3%) 0.17 
> than 5kg weight loss 55/86 (64%) 14/34 (41%) 0.02 
Steroids for 1
st
 flare 45/86 (52%) 20/34 (59%) 0.52 
Extra-intestinal manifestations 20/86 (23%) 8/34 (24%) 0.98 
*All continuous variables are recorded as medians (IQR) 
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Table 2: Laboratory and histological predictors of DCD at diagnosis 
 Disabling CD 
N=86 
Non-disabling CD  
N=34 
p 
Haemoglobin* 11.95 (10.3-12.6) 12 (10.5-12.8) 0.96 
White cell count* 10.43 (7.2-13.95) 10 (± 6.23-14) 0.36 
 Platelet count* 430.5 (333-538) 395(313-504) 0.6 
Serum albumin* 35.5 (33-41) 35.5 (32-39) 0.96 
Ferritin* 50 (33-74) 69 (63-88) 0.31 
 CRP* 27.5 (12-62) 36 (12-65) 0.82 
Granulomas  38/86 12/34 0.37 
*All continuous variables are recorded as medians (IQR) 
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Figure 1: Kaplan-Meier curves for the development of SCD 
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Figure 2: Kaplan-Meier curves for the development of SCD according to the presence 
or absence of perianal disease and granulomas at diagnosis in patients with B1 
phenotype 
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Table 3 Clinical and demographic risk factors at diagnosis significantly associated with 
time to development of SCD, analysed with Cox proportional hazard method 
Risk factors at 
diagnosis 
Non-severe  
N=75 (%) 
Severe CD 
N=45 (%) 
Unadjusted Adjusted 
HR         95% CI            p HR          95% CI              p 
Female gender 50/75(67%) 22/45 (49%) 0.56       0.31-1.0         0.05 0.59        0.32-1.1            0.1 
Race 
White 
Black 
Coloured 
 
14/75 (19%) 
5/75 (7%) 
55/75 (73%) 
 
8/45 (18%) 
2/45 (4%) 
35/45 (78%) 
 
1             Ref               0.98 
0.75        0.16-3.55       
0.98        0.46-2.12       
Not included 
Age 
A1, <17 
A2, 17-40 
A3, >40 
 
4/75 (5%) 
50/75 (67%) 
21/75 (28%) 
 
5/45 (11%) 
32/45 (71%) 
8/45 (18%) 
 
1             Ref               0.20 
0.60        0.23-1.55       
0.45        0.15-1.39       
 
1             Ref     
0.48        0.18-1.32        0.16 
0.43        0.13-1.41        0.16 
Behaviour 
B1 
B2 
B3 
 
67/75 (89%) 
3/75 (4%) 
5/75 (7%) 
 
34/45 (76%) 
4/45 (9%) 
7/45 (16%) 
 
1             Ref                0.006 
2.29        0.81-6.49 
2.89        1.26-6.66 
 
1             Ref 
4.62        1.46-14.61      0.01 
2.93        1.23-7.0          0.02   
Perianal disease 5/75 (7%) 11/45 (24%) 3.05        1.54-6.04      0.001 3.44        1.63-7.24        0.001 
Location 
L1 
L2 
L3 
 
27/75 (36%) 
23/75 (31%) 
25/75 (33%) 
 
21/45 (47%) 
7/45 (16%) 
16/45 (36%) 
 
1             Ref                  0.80        
0.63        0.28-1.42 
0.94        0.49-1.81 
Not included 
Extent of 
SB>20cm 
25/75 (20%) 17/45 (38%) 1.78        0.97-3.27        0.03 1.01        0.99-1.03         0.16 
Colonic 
segments 
involved 
2 (0-3) 1 (0-3) 0.94        0.8-1.11          0.45 Not included 
Upper GIT  3/75 (4%) 3/45 (7%) 1.32        0.41-4.28       0.65 Not included 
Rectal 
involvement  
13/75 (17%) 6/45 (13%) 0.8          0.34-1.89       0.61 Not included 
Family history   6/75 (8%) 5/45 (11%) 1.49        0.59-3.78       0.41 Not included 
Current smoker 51/75 (68%) 27/45 (60%) 0.65        0.36-1.18       0.80 Not included 
Appendicectomy 5/75 (7%) 5/45 (11%) 1.39        0.55-3.52       0.49 Not included 
> than 5kg 
weight loss 
37/75 (49%) 32/45 (71%) 2.15        1.12-4.1         0.02 1.18         0.9-3.45           0.1 
Steroids  41/75 (55%) 24/45(53%) 1.08        0.6-1.94         0.80 Not included 
EIM* 19/75 (25%) 9/45 (20%) 0.7          0.33-1.45       0.33 Not included 
*Extra-intestinal manifestations; HR: hazards ratio, 95% CI: 95% confidence interval 
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Table 4 Laboratory and histological parameters at diagnosis associated with time to 
development of SCD, analysed with Cox proportional hazard method 
 
Risk factors at 
diagnosis  
Non-severe 
N=75 (%) 
Severe CD 
N=45 (%) 
 
Unadjusted Adjusted 
HR         95%CI              p HR        95% CI              p 
Haemoglobin* 56/75 (75%) 37/45 (82%) 1.55        0.72-3.34      0.26 Not included 
White cell 
count† 
34/75 (45%) 26/45 (58%) 1.39        0.77-2.52      0.27 Not included 
Platelet count † 48/75 (64%) 28/45 (62%) 1.19        0.65-2.18      0.57 Not included 
CRP † 63/75 (84%) 40/45 (89%) 0.77        0.28-2.18      0.63 Not included 
Albumin* 27/75 (36%) 18/45 (40%) 1.18        0.65-2,14      0.60 Not included 
Granulomas 24/75 (32%) 26/45 (58%) 2             1.12-3.66      0.02 2.39       1.25-4.59        0.009 
*Treated as a categorical variable: within the normal reference range or below the normal 
reference range 
†Treated as a categorical variable: within the normal reference range or above the normal 
reference range 
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Appendix 2: South African Medical Journal Author Guidelines 
AUTHORSHIP 
Named authors must consent to publication. Authorship should be based on substantial 
contribution to: (i) conception, design, analysis and interpretation of data; (ii) drafting or 
critical revision for important intellectual content; and (iii) approval of the version to be 
published. These conditions must all be met (uniform requirements for manuscripts submitted 
to biomedical journals; refer to www.icmje.org). 
CONFLICT OF INTEREST 
Authors must declare all sources of support for the research and any association with a 
product or subject that may constitute conflict of interest. 
RESEARCH ETHICS COMMITTEE APPROVAL 
Provide evidence of Research Ethics Committee approval of the research where relevant. 
PROTECTION OF PATIENT'S RIGHTS TO PRIVACY 
Identifying information should not be published in written descriptions, photographs, and 
pedigrees unless the information is essential for scientific purposes and the patient (or parent 
or guardian) gives informed written consent for publication. The patient should be shown the 
manuscript to be published. Refer to www.icmje.org. 
ETHNIC CLASSIFICATION 
References to ethnic classification must indicate the rationale for this. 
MANUSCRIPTS 
Shorter items are more likely to be accepted for publication, owing to space constraints and 
reader preferences.  
Research articles (previously 'Original articles') not exceeding 3 000 words, with up to 6 
tables or illustrations, are usually observations or research of relevance to clinical medicine 
and related fields. References should preferably be limited to no more than 15. Please provide 
a structured abstract not exceeding 250 words, with the following recommended headings: 
Background, Objectives, Methods, Results, and Conclusion. 
MANUSCRIPT PREPARATION 
Qualification, affiliation and contact details of ALL authors must be provided in the 
manuscript and in the online submission process. 
Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and 
haemoglobin (g/dl). Litres are denoted with a lowercase 'l' e.g. 'ml' for millilitres). Units 
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should be preceded by a space (except for %), e.g. '40 kg' and '20 cm' but '50%'. 
Greater/smaller than signs (> and <) should be placed immediately preceding the relevant 
number, i.e. 'women >40 years of age'. The same applies to ± and º, i.e. '35±6' and '19ºC'. 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160... 
Quotes should be placed in single quotation marks: i.e. the respondent stated: '...' 
Round brackets (parentheses) should be used, as opposed to square brackets, which are 
reserved for denoting concentrations or insertions in direct quotes. 
General formatting 
The manuscript must be in Microsoft Word or RTF document format. Text must be single-
spaced, in 12-point Times New Roman font, and contain no unnecessary formatting (such as 
text in boxes, with the exception of Tables). 
ILLUSTRATIONS AND TABLES 
If tables or illustrations submitted have been published elsewhere, the author(s) should 
provide consent to republication obtained from the copyright holder.  
Tables may be embedded in the manuscript file or provided as 'supplementary files'. They 
must be numbered in Arabic numerals (1,2,3...) and referred to consecutively in the text (e.g. 
'Table 1'). Tables should be constructed carefully and simply for intelligible data 
representation. Unnecessarily complicated tables are strongly discouraged. Tables must be 
cell-based (i.e. not constructed with text boxes or tabs), and accompanied by a concise title 
and column headings. Footnotes must be indicated with consecutive use of the following 
symbols: * † ‡ § ¶ || then ** †† ‡‡ etc.  
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. Figure 
legends: Fig. 1. 'Title...' 
All illustrations/figures/graphs must be of high resolution/quality: 300 dpi or more is 
preferable, but images must not be resized to increase resolution. Unformatted and 
uncompressed images must be attached individually as 'supplementary files' upon 
submission (not solely embedded in the accompanying manuscript). TIFF and PNG formats 
are preferable; JPEG and PDF formats are accepted, but authors must be wary of image 
compression. Illustrations and graphs prepared in Microsoft Powerpoint or Excel must be 
accompanied by the original workbook.  
REFERENCES 
Authors must verify references from the original sources. Only complete, correctly formatted 
reference lists will be accepted. Reference lists must be generated manually and not with the 
use of reference manager software.  
References should be inserted in the text as superscript numbers, e.g. These regulations are 
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endorsed by the World Health Organization,
2
 and others.
3,4,6
 
All references should be listed at the end of the article in numerical order of appearance in the 
Vancouver style (not alphabetical order). Approved abbreviations of journal titles must be 
used; see the List of Journals in Index Medicus.  
Names and initials of all authors should be given; if there are more than six authors, the first 
three names should be given followed by et al. First and last page, volume and issue numbers 
should be given. 
Wherever possible, references must be accompanied by a digital object identifier (DOI) 
link and PubMed ID (PMID)/PubMed Central ID (PMCID). Authors are encouraged to 
use the DOI lookup service offered by CrossRef. 
Journal references: 
Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about glaucoma. Stat Med 
1998;289:350-355. [http://dx.doi.org/10.1000/hgjr.182] [PMID: 2764753] 
Book references: 
Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 1975:96-101.  
Chapter/section in a book: 
Weinstein L, Swartz MN. Pathogenic properties of invading microorganisms. In: Sodeman 
WA jun, Sodeman WA, eds. Pathologic Physiology: Mechanisms of Disease. Philadelphia: 
WB Saunders, 1974:457-472. 
Internet references: 
World Health Organization. The World Health Report 2002 - Reducing Risks, Promoting 
Healthy Life. Geneva: World Health Organization, 2002. http://www.who.int/whr/2002 
(accessed 16 January 2010). 
Other references (e.g. reports) should follow the same format: 
Author(s). Title. Publisher place: publisher name, year; pages.  
Cited manuscripts that have been accepted but not yet published can be included as 
references followed by '(in press)'.  
Unpublished observations and personal communications in the text must not appear in the 
reference list. The full name of the source person must be provided for personal 
communications e.g. '...(Prof. Michael Jones, personal communication)'. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
55 
 
Appendix 3 
 
 Classification of Crohn’s Disease according to the Montreal Classification 
 
Age at diagnosis 
A1:  16 yr and under  
A2:  17–40 yr  
A3:  Over 40 yr 
 
Location  
L1:  Ileal  
L2:  Colonic  
L3:  Ileocolonic  
L4:  Isolated upper GIT 
 
Behaviour 
B1:  Non-stricturing, non-penetrating (inflammatory)  
B2:  Stricturing  
B3:  Penetrating  
P†   Perianal disease modifier 
 
L4 can be added to locations L1–L3 to indicate coexisting upper GI disease. 
†P can be added to any behaviour to indicate coexisting perianal disease. 
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567 subjects with CD 
on IBD clinic database 
Appendix 4 
Study subject eligibility 
257 had disease 
duration less than 
5 years 
310 subjects had 
disease duration 
exceeding 5 years 
151 had no 
baseline data or 
incomplete 
baseline data 
18 had complex 
perianal disease at 
diagnosis 
9 required 
immediate surgery 
(within 1 month of 
diagnosis) 
2 had reversal of 
initial diagnosis to 
UC 
120 subjects eligible 
for study inclusion 
10 subjects were 
lost to follow up 
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Appendix 5: A summary of predictors of poor outcome CD 
 
Outcome Predictor Reference 
Severe CD Significant weight loss at diagnosis 
 
Stricturing CD (B2) at diagnosis 
Loly et al. (2008) 
Disabling CD Age at diagnosis 
 
Corticosteroids for the first flare, 
 
Perianal disease 
Beaugerie et al. (2006) 
Disabling CD Perianal disease at diagnosis 
 
Corticosteroids to treat the first flare  
 
Ileo-colonic location (L3)  
 Loly et al. (2008) 
CD recurrence rates Young age at diagnosis 
 
Current smoking 
Romberg-Camps et al. 
(2009) 
Progression to 
complicated disease 
(B1 to B2 or B3) 
Small bowel location, perianal disease  
 
Genetic markers 
Tarrant et al. (2009) 
Adler et al. (2011) 
Surgery Ileal location 
Serlogical markers 
Genetic markers 
Granulomas 
Young age at diagnosis 
Penetrating behaviour at diagnosis 
Stricturing disease at diagnosis 
Smoking 
Solberg et al. ( 2007); 
Romberg-Camps et al. 
(2009) 
Dubinsky et al. (2008) 
Adler et al (2011) 
Heresbach et al. (2005) 
Romberg-Camps et al. 
(2009) 
Solberg et al. ( 2007) 
Romberg-Camps et al. 
(2009) 
Latakos et al. (2007) 
Colectomy Deep colonic ulcers Allez et al. (2002) 
 
